Related Experiment Video
Updated: Apr 22, 2026
Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Characterization of S628N: a novel KIT mutation found in a metastatic melanoma
Abstract:
IMPORTANCE The KIT receptor is mutated in approximately 15%of acral, mucosal, and chronic, sun-damaged melanomas. The status of KIT mutations is of interest because they usually are mutually exclusive with N-RAS and B-RAF mutations and because of the availability of KIT kinase inhibitors in the clinic. Some recurrent KIT mutations are well characterized; others are poorly described.OBSERVATIONS We describe a novel KIT mutation in a patient with metastatic melanoma. The mutation, located in exon 13, resulted in S628N substitution in the KIT receptor. Using all-atom molecular dynamics simulations, biochemical assays, and cell-based assays, we showed that the mutation is a bona fide gain-of-function oncogenic mutation. Furthermore,we evaluated the sensitivity of the mutant to imatinib and dasatinib.CONCLUSIONS AND RELEVANCE We report a novel KIT gain-of-function mutation with S628N substitution (exon 13) and show that it is sensitive to imatinib in vitro. Therefore, patients with this mutation may be eligible for KIT kinase inhibitor–based therapy. Further studies are needed to evaluate the clinical benefit of such therapy.
Insights
Researchers identified a new KIT mutation (S628N) in melanoma that drives cancer growth. This mutation showed sensitivity to imatinib, suggesting a potential new treatment for patients with this specific KIT mutation.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The KIT receptor tyrosine kinase is a key driver in approximately 15% of melanomas, particularly acral, mucosal, and chronic sun-damaged subtypes.
- KIT mutations are clinically relevant due to their mutual exclusivity with common N-RAS and B-RAF mutations and the availability of targeted KIT inhibitors.
- While some KIT mutations are well-characterized, others remain poorly understood, necessitating further investigation.
Observation:
- A novel KIT mutation, S628N substitution in exon 13, was identified in a patient with metastatic melanoma.
- Advanced computational and experimental methods, including all-atom molecular dynamics simulations and various biochemical and cell-based assays, were employed to characterize this mutation.
- The study aimed to elucidate the oncogenic potential and therapeutic sensitivity of this newly discovered KIT mutation.
Findings:
- The S628N substitution in KIT was confirmed as a gain-of-function oncogenic mutation, promoting tumor growth.
- In vitro studies demonstrated that melanoma cells harboring the S628N KIT mutation exhibit sensitivity to the KIT kinase inhibitor imatinib.
- The mutation's sensitivity profile was also assessed against dasatinib, providing comparative data.
Implications:
- This discovery identifies a novel actionable target in melanoma, offering potential therapeutic avenues for patients with the S628N KIT mutation.
- Patients with this specific KIT mutation may benefit from treatment with imatinib or other KIT kinase inhibitors.
- Further clinical studies are warranted to definitively establish the efficacy and clinical benefit of KIT inhibitor-based therapies for this patient subgroup.
